Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Multiple Sclerosis 2Carcinoma in Situ 2Sarcoma, Kaposi 1Multiple Sclerosis, Relapsing-Remitting 1Multiple Sclerosis, Chronic Progressive 1HIV Infections 1Acquired Immunodeficiency Syndrome 1

Interventions

Cyclophosphamide 1495Cisplatin 1431Paclitaxel 1339Radiotherapy 1308Carboplatin 1264Gemcitabine 1225Docetaxel 1134Bevacizumab 1068Fluorouracil 906Doxorubicin 799Dexamethasone 753Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 693Etoposide 674Irinotecan 639Filgrastim 624Nivolumab 585Cytarabine 585Leucovorin 582Vincristine 512Cetuximab 478Prednisone 477Bortezomib 472Trastuzumab 469Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 443Lenalidomide 434

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Interferon beta-1b × Clear all
NCT02486640 2023-07-24

BETAPREDICT

Bayer

Completed
162 enrolled

Carcinoma in Situ, Multiple Sclerosis

NCT00000695 2021-11-02

Open Label Phase I Study To Evaluate the Safety of Combination Therapy With AZT and Interferon-Beta in Patients With AIDS Related Kaposi's Sarcoma

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 1 Completed
36 enrolled
Sarcoma

Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi, HIV Infections

NCT03134573 2019-03-26

PROmyBETAapp

Bayer

Completed
96 enrolled

Carcinoma in Situ, Multiple Sclerosis, Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Relapsing-Remitting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡